Skip to content
★ Sign in to follow
Akeso, Inc. logo

Akeso, Inc. Stock: price and insider trades · Hong Kong

HK·Mcap HK$84.4BHealth Care

No insider purchase over the last 90 days. The latest, by Li Baiyong, was filed 31 Jul 2026.

Insider Decl.
48
Thresholds
n/a
Buy Volume
€3M
17 ops. · all time
Sell Volume
€147M
24 ops. · all time

Who traded when

BuySale
Xia Yu4 buys2 sales
Zhang Peng3 buys
Li Baiyong1 buy1 sale
Tan Bo2 buys
Wang Zhongmin Maxwell2 buys
Xu Yan2 buys

+1 other insider

Since the insiders bought

  • Filed 16 Jun 2026 · 145 days ago · €1.0M
    +2.6%
    Entry HK$83.90 · Close 22 Oct 2026 HK$86.10
  • Filed 16 Jun 2026 · 145 days ago · €578k
    +2.6%
    Entry HK$83.90 · Close 22 Oct 2026 HK$86.10

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Akeso, Inc. Strong Buy (bullish), based on 21 analysts. Average price target: HK$154.13.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 20,731 of 26,897 companies
32.9
score / 100
Value
29
Quality
37
FCF yld-2.2%
Earn yld-1.4%
EV/EBITDA·
ROE-14%
Gross mgn79%
Net mgn-36%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$91.65
Analyst consensus
21 analysts
Strong buy
HK$104.38Target HK$154.13(+68%)HK$227.19
Income statement
RevenueHK$3.1B
Gross profitHK$2.4B79% margin
EBITDA-HK$747.9M-24% margin
Net income-HK$1.1B-28.0% margin
Valuation
PER (forward)74.1x
P/Book8.5x
Beta-0.03
Balance sheet & cash
Market capHK$84.4B
Total debtHK$4.6B
Free Cash Flow-HK$1.7B
Debt / Equity60%
Profitability & ownership
ROE-13.6%
ROA-4.5%
% insiders21.2%
% institutions32.1%
Last declaration on 31 July 2026
Declarations48 total
  • ▲
    DirectorExecutives
    0HKEX
    450,000 sharesShareXHKGHKEX:DA20260731E00235
    Canonical exit: 22 Oct 2026 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    15,000 sharesShareXHKGHKEX:DA20260730E00562
    Canonical exit: 22 Oct 2026 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    130,000 sharesShareXHKGHKEX:DA20260731E00237
    Canonical exit: 22 Oct 2026 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    900,000 sharesShareXHKGHKEX:DA20260731E00233
    Canonical exit: 22 Oct 2026 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    15,000 sharesShareXHKGHKEX:DA20260730E00554
    Canonical exit: 22 Oct 2026 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    90,000 sharesShareXHKGHKEX:DA20260731E00247
    Canonical exit: 22 Oct 2026 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    15,000 sharesShareXHKGHKEX:DA20260730E00536
    Canonical exit: 22 Oct 2026 (T+90)
  • ▲
    DirectorExecutives
    9M HKD28HKEX
    100,000 shares@ HK$94.066551.8% of flowShareXHKGHKEX:DA20260616E00188
    Canonical exit: 13 Sept 2026 (T+90)
  • ▲
    DirectorExecutives
    5M HKD31HKEX
    60,000 shares@ HK$87.43100.0% of flowShareXHKGHKEX:DA20260615E00420
    Canonical exit: 10 Sept 2026 (T+90)
  • ▲
    DirectorExecutives
    9M HKD28HKEX
    100,000 shares@ HK$87.563548.2% of flowShareXHKGHKEX:DA20260615E00307
    Canonical exit: 9 Sept 2026 (T+90)
  • ▼
    DirectorExecutives
    224M HKD31HKEX
    1,500,000 shares@ HK$149.5481.4% of flowShareXHKGHKEX:DA20250905E00581
  • ▼
    DirectorExecutives
    449M HKD29HKEX
    3,000,000 shares@ HK$149.5460.1% of flowShareXHKGHKEX:DA20250905E00568
  • ▲
    DirectorExecutives
    0HKEX
    15,000 sharesShareXHKGHKEX:DA20250607E00016
    Canonical exit: 22 Aug 2025 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    15,000 sharesShareXHKGHKEX:DA20250607E00015
    Canonical exit: 22 Aug 2025 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    15,000 sharesShareXHKGHKEX:DA20250607E00014
    Canonical exit: 22 Aug 2025 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    250,000 sharesShareXHKGHKEX:DA20250603E00016
    Canonical exit: 22 Aug 2025 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    5,000,000 sharesShareXHKGHKEX:DA20250603E00020
    Canonical exit: 22 Aug 2025 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    250,000 sharesShareXHKGHKEX:DA20250603E00011
    Canonical exit: 22 Aug 2025 (T+90)
  • ▼
    DirectorExecutives
    9M HKD26HKEX
    124,000 shares@ HK$73.76371.4% of flowShareXHKGHKEX:DA20241203E00281
  • ▼
    DirectorExecutives
    143M HKD32HKEX
    2,000,000 shares@ HK$71.4862.1% of flowShareXHKGHKEX:DA20241203E00276
  • ▼
    DirectorExecutives
    94M HKD27HKEX
    1,308,000 shares@ HK$72.228214.1% of flowShareXHKGHKEX:DA20241203E00280
  • ▼
    DirectorExecutives
    71M HKD34HKEX
    1,000,000 shares@ HK$71.4593.8% of flowShareXHKGHKEX:DA20241203E00278
  • ▼
    DirectorExecutives
    55M HKD12HKEX
    740,000 shares@ HK$74.77118.2% of flowShareXHKGHKEX:DA20241203E00267
  • ▼
    DirectorExecutives
    48M HKD28HKEX
    1,000,000 shares@ HK$48.1518.6% of flowShareXHKGHKEX:DA20231130E00008
  • ▼
    DirectorExecutives
    96M HKD27HKEX
    2,000,000 shares@ HK$48.1513.7% of flowShareXHKGHKEX:DA20231130E00007

25 of 48 declarations

About Akeso, Inc.

Akeso, Inc., a healthcare company listed on the Hong Kong stock exchange and valued at HKD 84.4 billion, has large sales in its record. On September 1, 2025, Xia Yu (Director) sold EUR 49,106,843 and Li Baiyong (Director) sold EUR 24,553,421; on November 29, 2024, Wang Zhongmin Maxwell (Director) sold EUR 17,384,364. Of 24 sales, 15 carry an amount: EUR 146,679,022 in all, median EUR 5,613,375.

There are 17 purchases, 3 of them with an amount worth EUR 2,579,213 (median EUR 965,318); they make up 41% of open-market trades. The three largest date from June 2026: EUR 1,035,588 (Xia Yu, on June 15), EUR 965,318 (Xia Yu, on June 11) and EUR 578,307 (Zhang Peng, on June 12). On July 24, 2026, 7 filers bought on the same day. Across the full history, 3 purchase filings are classed as clustered.

Read moreShow less

The record holds 48 filings published between May 8, 2020 and July 31, 2026, from 8 filers. Xia Yu signs 21, of which 5 purchases and 13 sales. Annual volume goes from 1 filing in 2022 to 13 in 2023, then 10 in 2026, all purchases over the last twelve months. Median publication delay: 4 days. Insiders hold 21.2% of the capital.